Jennifer I. Moss
Oncology R&D
Cambridge, ENG, United Kingdom
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
An Inducible BRCA1 Expression System with In Vivo Applicability Uncovers Activity of the Combination of ATR and PARP Inhibitors to Overcome Therapy Resistance.
Journal: Cancers
Published: December 12, 2025
HER2-targeted star polymer conjugates for improved tumor distribution and efficacy.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: November 19, 2024
Multiomic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradation.
Journal: Science signaling
Published: February 27, 2024
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer.
Journal: British journal of cancer
Published: September 25, 2023
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
Journal: NPJ breast cancer
Published: September 19, 2023
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
Journal: NPJ breast cancer
Published: August 18, 2023
Impact of the physical-chemical properties of poly(lactic acid)-poly(ethylene glycol) polymeric nanoparticles on biodistribution.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: June 30, 2023
Epitope Lability of Phosphorylated Biomarkers of the DNA Damage Response Pathway Results in Increased Vulnerability to Effects of Delayed or Incomplete Formalin Fixation.
Journal: The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
Published: April 29, 2023
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.
Journal: Cancer research
Published: March 03, 2023
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
Journal: NPJ breast cancer
Published: October 19, 2022
Histopathological biomarkers for predicting the tumour accumulation of nanomedicines.
Journal: Nature biomedical engineering
Published: October 10, 2022
A preclinical model of peripheral T-cell lymphoma GATA3 reveals DNA damage response pathway vulnerability.
Journal: EMBO molecular medicine
Published: February 02, 2022
Last Updated: 09/26/2026